Mutant p53-dependent mitochondrial metabolic alterations in a mesenchymal stem cell-based model of progressive malignancy.


Journal

Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445

Informations de publication

Date de publication:
09 2019
Historique:
received: 07 06 2018
accepted: 08 10 2018
revised: 28 09 2018
pubmed: 11 11 2018
medline: 1 9 2020
entrez: 11 11 2018
Statut: ppublish

Résumé

It is well accepted that malignant transformation is associated with unique metabolism. Malignant transformation involves a variety of cellular pathways that are associated with initiation and progression of the malignant process that remain to be deciphered still. Here we used a mouse model of mutant p53 that presents a stepwise progressive transformation of adult Mesenchymal Stem Cells (MSCs). While the established parental p53Mut-MSCs induce tumors, the parental p53WT-MSCs that were established in parallel, did not. Furthermore, tumor lines derived from the parental p53Mut-MSCs (p53Mut-MSC-TLs), exhibited yet a more aggressive transformed phenotype, suggesting exacerbation in tumorigenesis. Metabolic tracing of these various cell types, indicated that while malignant transformation is echoed by a direct augmentation in glycolysis, the more aggressive p53Mut-MSC-TLs demonstrate increased mitochondrial oxidation that correlates with morphological changes in mitochondria mass and function. Finally, we show that these changes are p53Mut-dependent. Computational transcriptional analysis identified a mitochondrial gene signature specifically downregulated upon knock/out of p53Mut in MSC-TLs. Our results suggest that stem cells exhibiting different state of malignancy are also associated with a different quantitative and qualitative metabolic profile in a p53Mut-dependent manner. This may provide important insights for cancer prognosis and the use of specific metabolic inhibitors in a personalized designed cancer therapy.

Identifiants

pubmed: 30413783
doi: 10.1038/s41418-018-0227-z
pii: 10.1038/s41418-018-0227-z
pmc: PMC6748146
doi:

Substances chimiques

Mutant Proteins 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1566-1581

Références

Am J Hum Genet. 2000 Nov;67(5):1104-9
pubmed: 11013136
Nature. 2001 Nov 1;414(6859):105-11
pubmed: 11689955
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683
Genet Med. 2004 Mar-Apr;6(2):73-80
pubmed: 15017329
Nat Rev Cancer. 2005 Apr;5(4):275-84
pubmed: 15803154
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
J Immunol Methods. 2006 Apr 20;311(1-2):117-29
pubmed: 16563425
Science. 2006 Jun 16;312(5780):1650-3
pubmed: 16728594
Cell. 2006 Jul 14;126(1):107-20
pubmed: 16839880
Nature. 2008 Apr 3;452(7187):650-3
pubmed: 18385740
Cancer Res. 1991 Nov 15;51(22):6094-7
pubmed: 1933872
Nat Rev Cancer. 2009 Oct;9(10):701-13
pubmed: 19693097
Nat Rev Cancer. 2009 Oct;9(10):691-700
pubmed: 19759539
Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7455-60
pubmed: 20378837
J Exp Med. 2010 Sep 27;207(10):2127-40
pubmed: 20696700
Science. 2010 Dec 3;330(6009):1340-4
pubmed: 21127244
Nature. 2011 Jan 20;469(7330):314-22
pubmed: 21248838
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Stem Cell Rev Rep. 2011 Sep;7(3):560-8
pubmed: 21437576
FEBS J. 2011 Nov;278(22):4243-51
pubmed: 21929724
Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16259-64
pubmed: 21930938
Cell. 2012 Jan 20;148(1-2):244-58
pubmed: 22265415
Biochim Biophys Acta. 2012 Sep;1823(9):1604-16
pubmed: 22554985
J Physiol. 2012 Jul 15;590(14):3349-60
pubmed: 22586215
Genes Dev. 2012 Sep 1;26(17):1926-44
pubmed: 22899010
Antioxid Redox Signal. 2013 Aug 1;19(4):331-43
pubmed: 23320803
Cell Stem Cell. 2013 Mar 7;12(3):329-41
pubmed: 23333149
N Engl J Med. 2013 Mar 14;368(11):1027-32
pubmed: 23484829
Neurology. 2013 Apr 23;80(17):1577-83
pubmed: 23553477
Nat Commun. 2013;4:2935
pubmed: 24343302
Mol Cancer Res. 2014 Jan;12(1):3-13
pubmed: 24442106
Nat Cell Biol. 2014 Apr;16(4):357-66
pubmed: 24658687
Cell Death Differ. 2014 Sep;21(9):1419-31
pubmed: 24832469
Nature. 2014 Oct 30;514(7524):628-32
pubmed: 25119024
Methods Mol Biol. 2015;1241:23-38
pubmed: 25308485
Sci Rep. 2015 Jul 15;5:12410
pubmed: 26174737
Cell Metab. 2015 Oct 6;22(4):590-605
pubmed: 26365176
Cancer Cell. 2015 Dec 14;28(6):815-829
pubmed: 26678341
Curr Opin Genet Dev. 2016 Jun;38:16-22
pubmed: 27003724
Exp Hematol. 2016 Sep;44(9):866-873.e4
pubmed: 27118043
Br J Cancer. 2016 Jun 14;114(12):1305-12
pubmed: 27219018
Cold Spring Harb Perspect Med. 2016 Oct 3;6(10):null
pubmed: 27235476
Cell Metab. 2016 Jul 12;24(1):104-17
pubmed: 27411012
Cell. 2016 Jul 28;166(3):555-566
pubmed: 27471965
Nature. 2017 Jan 12;541(7636):222-227
pubmed: 27798600
J Clin Invest. 2017 Jan 3;127(1):132-136
pubmed: 27869650
Cold Spring Harb Protoc. 2016 Dec 1;2016(12):
pubmed: 27934682
Nat Med. 2017 Oct 6;23(10):1124-1134
pubmed: 28985214
Mol Cell Biol. 2017 Nov 28;37(24):
pubmed: 28993478
Oxid Med Cell Longev. 2017;2017:5047168
pubmed: 29018510
Cancer Res. 2018 Oct 15;78(20):5833-5847
pubmed: 30154152
Blood. 1988 Aug;72(2):567-72
pubmed: 3165295
Proc Natl Acad Sci U S A. 1984 Mar;81(5):1371-4
pubmed: 6143319
Nature. 1994 Feb 17;367(6464):645-8
pubmed: 7509044
J Exp Med. 1996 Apr 1;183(4):1797-806
pubmed: 8666936
Nat Med. 1997 Jul;3(7):730-7
pubmed: 9212098

Auteurs

Giuseppe Lonetto (G)

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, 76100, Israel.

Gabriela Koifman (G)

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, 76100, Israel.

Alon Silberman (A)

Department of Biological Regulation, Weizmann Institute of Science, Rehovot, 76100, Israel.

Ayush Attery (A)

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, 76100, Israel.

Hilla Solomon (H)

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, 76100, Israel.

Smadar Levin-Zaidman (S)

Department of Chemical Research Support, Weizmann Institute of Science, Rehovot, 76100, Israel.

Naomi Goldfinger (N)

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, 76100, Israel.

Ziv Porat (Z)

Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, 76100, Israel.

Ayelet Erez (A)

Department of Biological Regulation, Weizmann Institute of Science, Rehovot, 76100, Israel.

Varda Rotter (V)

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, 76100, Israel. varda.rotter@weizmann.ac.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH